The FDA endorsed a ≥2-point reduction on a visual analogue scale for pain as a clinically meaningful endpoint for urcosimod in NCP. NCP is a chronic ocular pain syndrome with no FDA-approved therapies ...

DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast Track Designation ...

The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive ...

EDN announces this year’s winners of the Electronic Products Product of the Year Awards, selected by the editors.

Researchers at the Institute for Molecular Science (NINS, Japan) and SOKENDAI have demonstrated a more than 2000% voltage-induced enhancement of near-field nonlinear optical responses. To achieve this ...

In this phase 2a study, researchers aimed to determine whether donor fecal microbiota transplantation improved survival in mRCC patients receiving immunotherapy.

Adequate and healthy nutrition is important during the postpartum time to support wound healing, hormone balance, energy, ...

Shares of Bausch Health BHC were down 1.86% on Jan. 26. This was the second consecutive session when shares slid. BHC stock ...

NMD Pharma is accelerating ignaseclant’s clinical development in CMT alongside multiple near-term clinical catalysts across its neuromuscular pipeline, with Phase 2 studies in spinal muscular atrophy ...

CBeyond TM Phase 2a 26-week extension data update and interim results expected Q1 2026. CBeyond Phase 2a Data Monitoring Committee (DMC) meeting on December 14, 2025, continued to demonstrate ...